MTM Laboratories
Heidelberg
About MTM Laboratories
mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec(R) Histology Kit and CINtec(R) Cytology Kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4(TM) antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1,001 – 5,000
- Total funding: $109.7M
- Funding stage: M&A
- Last round: Series C (Nov 2010)
- Website: mtm-laboratories.com
- Phone: 520.222.4573
Industries & Categories
Biotechnology, Health Diagnostics, Medical
Canonical: https://fsome.com/organization/mtm-laboratories-2095109 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.